Literature summary for 3.4.21.68 extracted from

Wiegler, K.; Bonny, C.; Coquoz, D.; Hirt, L.
The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator (2008), Cerebrovasc. Dis., 26, 360-366.

Search for more literature for 3.4.21.68

Application

Application	Comment	Organism
medicine	although rtPA enhances ischemic damage, the dose of recombinant tPA used in clinics does not affect the powerful neuroprotection by the JNK inhibitor XG-102	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
additional information	addition of human recombinant tPA after ischemia, in a mouse model of transient 30-min-suture middle cerebral artery occlusion, enhances ischemic damage both in vitro and in vivo, but XG-102 is able to induce a significant neuroprotection. Addition of recombinant tPA after oxygen and glucose deprivation enhances neuronal death in CA1	Homo sapiens	?	-	?

Synonyms

Synonyms	Comment	Organism
Tissue plasminogen activator	-	Homo sapiens
tPA	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)